Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

Urology
Przemyslaw TwardowskiDavid R Gandara

Abstract

To determine whether aflibercept, a recombinant fusion protein that binds and neutralizes multiple vascular endothelial growth factor isoforms, is effective in the treatment of urothelial cancer. The efficacy of systemic therapies for advanced urothelial cancer after failure of front-line platinum-based chemotherapy is limited. Evidence has shown that vascular endothelial growth factor is important in the pathophysiology of urothelial cancer. Patients with measurable, metastatic, or locally advanced urothelial cancer previously treated with 1 platinum-containing regimen were enrolled. Aflibercept was administered at 4 mg/kg intravenously every 2 weeks. The response rate (RR) and progression-free survival (PFS) were assessed in a 2-stage accrual design (22 + 18). A maximum of 40 patients were to be accrued to rule out a null hypothesis RR of 4% and PFS of 3 months versus an alternative RR of 15% and PFS of 5.4 months, with α = 0.12 and β = 0.19. A total of 22 patients were accrued. One partial response (4.5% RR, 95% confidence interval 0.1%-22.8%) was seen. The median PFS was 2.79 months (95% confidence interval 1.74-3.88). Attributable Grade 3 toxicities included fatigue, hypertension, proteinuria, pulmonary hemorrhage, pain, h...Continue Reading

References

Jul 1, 1996·The Netherlands Journal of Medicine·H H LichtenbeldH F Hillen
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Aug 25, 2005·Journal of the American Chemical Society·Jianwen Jiang, Stanley I Sandler
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Dec 17, 2008·Molecular Cancer Therapeutics·Jie Ma, David J Waxman
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase

❮ Previous
Next ❯

Citations

Feb 19, 2013·Immunotherapy·David Xu, Peter K Kaiser
Apr 1, 2011·Clinical Investigation·Elizabeth A GuancialJonathan E Rosenberg
Oct 26, 2013·Future Oncology·Christina Ann Ortmann, Danish Mazhar
Apr 2, 2014·Current Opinion in Oncology·Monalisa GhoshAndrea B Apolo
Aug 10, 2011·Vascular Cell·Minhong Yan
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Ketao JinLisong Teng
Nov 26, 2011·Expert Review of Anticancer Therapy·Amy Q LeiChong-xian Pan
Dec 14, 2011·Expert Review of Anticancer Therapy·Carmel PezaroIan D Davis
Nov 18, 2011·Expert Opinion on Investigational Drugs·A A CrawshawH S Young
Oct 7, 2014·Expert Opinion on Investigational Drugs·Clarisse R MazzolaJoseph Chin
Nov 8, 2013·Expert Opinion on Emerging Drugs·Benjamin A Gartrell, Guru Sonpavde
Dec 4, 2012·Expert Opinion on Biological Therapy·Joel W Neal, Heather A Wakelee
Jun 23, 2015·Expert Opinion on Investigational Drugs·Clarisse R Mazzola, Joseph Chin
Oct 30, 2012·Clinical Colorectal Cancer·Edith P Mitchell
Jan 24, 2012·Cancer Treatment Reviews·Andrew Gaya, Vivien Tse
Apr 13, 2011·Trends in Molecular Medicine·Pipsa SaharinenKari Alitalo
Sep 24, 2015·Nature Reviews. Urology·Kim E M van KesselEllen C Zwarthoff
Aug 1, 2015·Critical Reviews in Oncology/hematology·Vincenzo RicciTeresa Fabozzi
Apr 14, 2016·Clinical Genitourinary Cancer·Sujata NarayananSandy Srinivas
Jul 22, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rita AzevedoLucio Lara Santos
Jun 25, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ling PengQiong Zhao
Apr 19, 2012·Expert Opinion on Therapeutic Targets·Bagi R P JanaGuru Sonpavde
Nov 6, 2010·MAbs·Janice M Reichert
Apr 2, 2015·Cancer Treatment Reviews·Emmanuel Seront, Jean-Pascal Machiels
Apr 4, 2015·Hematology/oncology Clinics of North America·Sujata NarayananSandy Srinivas
Apr 4, 2015·Hematology/oncology Clinics of North America·Guru SonpavdeCora N Sternberg
May 11, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth R Plimack, Daniel M Geynisman
Dec 13, 2017·Future Oncology·Panagiotis J VlachostergiosScott T Tagawa
Feb 17, 2017·Therapeutic Advances in Medical Oncology·Sujata Narayanan, Sandy Srinivas
Sep 13, 2011·Journal of Hematology & Oncology·Nabil IsmailiAude Flechon
Oct 18, 2019·Current Molecular Pharmacology·Samira BahramiAmirhossein Sahebkar
Apr 25, 2015·Oncotarget·Mahmoud ChehabDimitra Bourboulia
May 30, 2013·American Society of Clinical Oncology Educational Book·Andrea B Apolo, David J Kwiatkowski
May 4, 2020·World Journal of Urology·Sanaz GhafouriAlexandra Drakaki
Oct 13, 2019·Experimental & Molecular Medicine·Tae-Wook ChungKi-Tae Ha
Sep 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia A TangMalcolm J Moore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.